MA42665A - Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations - Google Patents

Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations

Info

Publication number
MA42665A
MA42665A MA042665A MA42665A MA42665A MA 42665 A MA42665 A MA 42665A MA 042665 A MA042665 A MA 042665A MA 42665 A MA42665 A MA 42665A MA 42665 A MA42665 A MA 42665A
Authority
MA
Morocco
Prior art keywords
diantibodies
binding
bispecific monovalent
bispecific
monovalent
Prior art date
Application number
MA042665A
Other languages
English (en)
French (fr)
Inventor
Ralph Alderson
Ezio Bonvini
Gurunadh Reddy Chichili
Ling Huang
Leslie S Johnson
Paul A Moore
Kalpana Shah
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of MA42665A publication Critical patent/MA42665A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA042665A 2015-08-17 2016-08-12 Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations MA42665A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206051P 2015-08-17 2015-08-17
US201662280318P 2016-01-19 2016-01-19

Publications (1)

Publication Number Publication Date
MA42665A true MA42665A (fr) 2018-06-27

Family

ID=58051498

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042665A MA42665A (fr) 2015-08-17 2016-08-12 Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations

Country Status (21)

Country Link
US (1) US20190002563A1 (OSRAM)
EP (1) EP3337507A4 (OSRAM)
JP (1) JP2018523686A (OSRAM)
KR (1) KR20180038045A (OSRAM)
CN (1) CN107921130A (OSRAM)
AU (1) AU2016307955A1 (OSRAM)
CA (1) CA2995709A1 (OSRAM)
CL (1) CL2018000422A1 (OSRAM)
CO (1) CO2018001485A2 (OSRAM)
CR (1) CR20180105A (OSRAM)
EA (1) EA201890443A1 (OSRAM)
EC (1) ECSP18011248A (OSRAM)
HK (1) HK1249423A1 (OSRAM)
IL (1) IL257562A (OSRAM)
MA (1) MA42665A (OSRAM)
MX (1) MX2018001954A (OSRAM)
PE (1) PE20181066A1 (OSRAM)
PH (1) PH12018500363A1 (OSRAM)
TW (1) TW201718652A (OSRAM)
WO (1) WO2017030926A1 (OSRAM)
ZA (1) ZA201800955B (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2718692C2 (ru) * 2014-05-29 2020-04-13 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
CU20170041A7 (es) 2014-09-26 2017-09-06 Macrogenics Inc Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
CA3053803A1 (en) 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
BR112019020940A2 (pt) 2017-04-11 2020-05-05 Inhibrx, Inc. construções polipeptídicas multipecíficas que têm ligação a cd3 restrita e métodos de usar as mesmas
BR112020004543A2 (pt) * 2017-09-08 2020-09-08 Maverick Therapeutics, Inc. proteínas de ligação ativadas condicionalmente restritas
CN109939230A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤耐顺铂膀胱癌细胞t24/ddp的应用
CN109939232A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞pumc-91的应用
CN109939231A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用
CN109939126A (zh) * 2017-12-21 2019-06-28 张曼 Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用
CN109971711A (zh) * 2017-12-27 2019-07-05 张曼 关于cd3×b7h3双特异性抗体定向杀伤人膀胱癌细胞的应用
EP3752196A4 (en) * 2018-02-15 2022-03-23 MacroGenics, Inc. CD3-BINDING DOMAIN VARIANTS AND THEIR USE IN COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES
IL323061A (en) 2018-04-11 2025-10-01 Inhibrx Biosciences Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
JP7453219B2 (ja) 2018-10-11 2024-03-19 インヒブリックス， インコーポレイテッド Ｐｄ－１単一ドメイン抗体およびその治療用組成物
WO2020076970A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
AU2019394241A1 (en) * 2018-12-07 2021-06-03 Jiangsu Hengrui Medicine Co., Ltd. CD3 antibody and pharmaceutical use thereof
WO2020114479A1 (zh) * 2018-12-07 2020-06-11 江苏恒瑞医药股份有限公司 多特异性蛋白分子
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技（成都）有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
EP3822288A1 (en) * 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
AU2020412595A1 (en) * 2019-12-23 2022-07-14 Macrogenics, Inc. Therapy for the treatment of cancer
KR20220148175A (ko) 2020-01-29 2022-11-04 인히브릭스, 인크. Ｃｄ28 단일 도메인 항체 및 이의 다가 및 다중특이적 구조체
WO2022232392A2 (en) * 2021-04-28 2022-11-03 Lyvgen Biopharma Holdings Limited Bi-specific antibodies comprising anti-b7h3 binding molecules
CN113527493B (zh) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
WO2023086772A1 (en) 2021-11-12 2023-05-19 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
CN114539420B (zh) * 2022-01-20 2024-05-17 荣昌生物制药(烟台)股份有限公司 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用
WO2025245264A1 (en) * 2024-05-21 2025-11-27 Briapro Therapeutics Corp. Anti-b7-h3 antibodies and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2982380B1 (en) * 2010-03-04 2021-09-01 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN107722124A (zh) * 2011-05-21 2018-02-23 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9487587B2 (en) * 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP3359192A4 (en) * 2015-10-08 2019-05-01 MacroGenics, Inc. COMBINATION THERAPY FOR CANCER TREATMENT

Also Published As

Publication number Publication date
US20190002563A1 (en) 2019-01-03
EP3337507A4 (en) 2019-04-24
CL2018000422A1 (es) 2018-08-10
AU2016307955A1 (en) 2018-03-08
EP3337507A1 (en) 2018-06-27
CA2995709A1 (en) 2017-02-23
JP2018523686A (ja) 2018-08-23
CR20180105A (es) 2018-06-12
CN107921130A (zh) 2018-04-17
PH12018500363A1 (en) 2018-09-10
EA201890443A1 (ru) 2018-09-28
KR20180038045A (ko) 2018-04-13
TW201718652A (zh) 2017-06-01
ECSP18011248A (es) 2018-04-30
MX2018001954A (es) 2018-11-09
CO2018001485A2 (es) 2018-07-10
HK1249423A1 (zh) 2018-11-02
WO2017030926A1 (en) 2017-02-23
PE20181066A1 (es) 2018-07-04
IL257562A (en) 2018-04-30
ZA201800955B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
MA42665A (fr) Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations
CY2024026I1 (el) Μορια προσδεσης pd-1 και μεθοδοι χρησης αυτων
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA47612A (fr) Molécules de liaison bispécifiques capables de se lier à cd137 et à des antigènes tumoraux, et leurs utilisations
IL256871B (en) Constructs for bispecific antibodies binding dll3 and cd3 and uses thereof
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
MA43186A (fr) Anticorps se liant spécifiquement à pd-1 et leurs utilisations
CL2018000281A1 (es) Anticuerpos monoclonales contra bcma
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
EP3377102A4 (en) ANTI-PD-1 ANTIBODIES AND THEIR THERAPEUTIC USES
MA46990A (fr) Compositions de glp-1 et leurs utilisations
PL3035965T4 (pl) Dwuswoiste jednowartościowe diaciała zdolne do wiązania CD123 i CD3 oraz ich zastosowania
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3328895A4 (en) ANTI-PD-1 ANTIBODIES AND USES THEREOF
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
SMT201600392B (it) Anticorpi bispecifici diretti contro cd3epsilon e bcma
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
IL244238B (en) Monovalent bispecific diabolites capable of binding to gpa33 and cd3 and their uses
EP3383904A4 (en) CTLA-4 ANTIBODIES AND USES THEREOF
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
EP3356416A4 (en) PD-1 ANTIBODIES AND USES THEREOF
EP3337486A4 (en) DEUTERIZED CONNECTIONS AND USES THEREOF
EP3349802A4 (en) LIPO CATIONIC DENDRIMERS AND USES THEREOF
MA41919A (fr) Hétéromultimères alk4:actriib et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations